PET/CT in Malignant Bone Disease

Einat Even-Sapir

doi:10.1055/s-2008-1060334

Seminars in Musculoskeletal Radiology, Inhaltsverzeichnis

Semin Musculoskelet Radiol 2007; 11(4): 312-321
DOI: 10.1055/s-2008-1060334

PET/CT in Malignant Bone Disease

Einat Even-Sapir¹

¹Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Abstract

ABSTRACT

The most commonly used positron emission tomography (PET) tracer in clinical practice, fluorine-18 fluorodeoxyglucose (¹⁸F-FDG) is a glucose analogue that directly gains entry in excess into tumor cells. It is therefore sensitive for the detection of early bone marrow involvement prior to any identifiable bone changes. The introduction of ¹⁸F-FDG-PET in the imaging algorithms of various malignant diseases often obviates the need to perform a separate assessment of malignant bone involvement with conventional bone scintigraphy. After therapy, disappearance of ¹⁸F-FDG accumulation indicates success even when the bone remains morphologically abnormal. Novel hybrid systems composed of PET and computed tomography (CT) allow for acquisition of both modalities in the same clinical setting and the generation of fused functional-anatomical images. This technique has been found to improve the diagnostic accuracy of PET in detecting malignant bone involvement. This article discusses the role of PET/CT, primarily ¹⁸F-FDG PET/CT, in the assessment of malignant bone involvement in patients with primary bone sarcomas, common solid malignancies, lymphoma, and multiple myeloma.

KEYWORDS

PET - ¹⁸F-FDG - bone - metastasis - sarcoma

Volltext

Referenzen

REFERENCES

1 Padhani A, Husband J. Bone metastases. In: Husband JES, Reznek RH Imaging in Oncology. Oxford; Isis Medical Media 1998: 765-787
2 Hamaoka T, Madewell J E, Podoloff D A, Hortobagyi G N, Ueno N T. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004; 22 2942-2953
3 Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med. 2005; 35 135-142
4 Angtuaco E JC, Fassas A BT, Walker R, Sethi R H, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology. 2004; 231 11-23
5 Galasko C S. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop Relat Res. 1982; 169 20-27
6 del Regato J A. Pathways of metastatic spread of malignant tumors. Semin Oncol. 1977; 4 33-38
7 Morgan-Parkes J H. Metastases: mechanisms, pathways, and cascades. AJR Am J Roentgenol. 1995; 164(5) 1075-1082
8 Kricun M E. Red-yellow marrow conversion: its effect on the location of some solitary bone lesions. Skeletal Radiol. 1985; 14(1) 10-19
9 Roodman G D. Mechanisms of bone metastasis. N Engl J Med. 2004; 350 1655-1664
10 Blake G M, Park-Holohan S J, Cook G J, Fogelman I. Quantitative studies of bone with the use of ¹⁸F-fluoride and ^99mTc-methylene diphosphonate. Semin Nucl Med. 2001; 31 28-49
11 Cook G J, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med. 2001; 31 50-61
12 Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005; 46 1356-1367
13 Aoki J, Watanabe H, Shinozaki T et al.. FDG PET of primary benign and malignant. bone tumors: standardized uptake value in 52 lesions. Radiology. 2001; 219 774-777
14 Dimitrakopoulou-Strauss A, Strauss L G, Heichel T et al.. The role of quantitative ¹⁸F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med. 2002; 43 510-518
15 Rohren E M, Turkington T G, Coleman R E. Clinical applications of PET in oncology. Radiology. 2004; 231 305-332
16 Cook G J, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer. 2000; 88 2927-2933
17 Franzius C, Sciuk J, Daldrup-Link H E, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000; 27 1305-1311
18 Liu F Y, Chang J T, Wang H M et al.. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2006; 24(4) 599-604
19 Cook G J, Houston S, Rubens R, Maisey M N, Fogelman I. Detection of bone metastases in breast cancer by ¹⁸FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998; 16 3375-3379
20 Burgman P, Odonoghue J A, Humm J L, Ling C C. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med. 2001; 42 170-175
21 Metser U, Lerman H, Blank A, Lievshitz G, Bokstein F, Even-Sapir E. Malignant involvement of the spine: assessment by ¹⁸F-Fluorodeoxyglucose PET/CT. J Nucl Med. 2004; 45 279-284
22 Schulte M, Brecht-Krauss D, Heymer B et al.. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med. 2000; 41 1695-1701
23 Folpe A L, Lyles R H, Sprouse J T, Conrad III E U, Eary J F. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000; 6 1279-1287
24 Gallowitsch H J, Kresnik E, Gasser J et al.. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003; 38 250-256
25 Israel O, Goldberg A, Nachtigal A et al.. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging. 2006; 33(11) 1280-1284
26 Sugawara Y, Fisher S J, Zasadny K R, Kison P V, Baker L H, Wahl R L. Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998; 16 173-180
27 Clamp A, Danson S, Nguyen H, Cole D, Clemons M. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 2004; 5 607-616
28 Kazama T, Swanston N, Podoloff D A, Macapinlac H A. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005; 32 1406-1411
29 Bar-Shalom R, Yefremov N, Guralnik L et al.. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003; 44 1200-1209
30 Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith S J. PET/CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004; 24 1411-1431
31 Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol. 2003; 5 26-31
32 Boogerd W, van der Sande J J, Kroger R. Early diagnosis and treatment of spinal epidural metastasis in breast cancer: a prospective study. J Neurol Neurosurg Psychiatry. 1992; 55 1188-1193
33 Schirrmeister H, Guhlmann A, Kotzerke J et al.. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999; 17 2381-2389
34 Even-Sapir E, Metser U, Flusser G et al.. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004; 45 272-278
35 Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high- risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006; 47 287-297
36 Brenner W, Bohuslavizki K H, Eary J F. PET imaging of osteosarcoma. J Nucl Med. 2003; 44 930-942
37 Hawkins D S, Schuetze S M, Butrynski J E et al.. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005; 23 8828-8834
38 Folpe A L, Lyles R H, Sprouse J T, Conrad III E U, Eary J F. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000; 6 1279-1287
39 Eary J F, O'Sullivan F, Powitan Y et al.. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002; 29 1149-1154
40 Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006; 33 683-691
41 Pezeshk P, Sadow C A, Winalski C S, Lang P K, Ready J E, Carrino J A. Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm. Acad Radiol. 2006; 13 1011-1015
42 Lodge M A, Lucas J D, Marsden P K et al.. A PET study of ¹⁸FDG uptake in soft tissue masses. Eur J Nucl Med. 1999; 26 22-30
43 Schleiermacher G, Peter M, Oberlin O et al.. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol. 2003; 21 85-91
44 Wuisman P, Enneking W F. Prognosis of patients who have osteosarcoma with skip metastasis. J Bone Joint Surg Am. 1990; 72 60-68
45 Cotterill S J, Ahrens S, Paulussen M et al.. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18 3108-3114
46 Franzius C, Daldrup-Link H E, Sciuk J et al.. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol. 2001; 12 479-486
47 Franzius C, Daldrup-Link H E, Wagner-Bohn A et al.. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol. 2002; 13 157-160
48 Paulussen M, Ahrens S, Burdach S et al.. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998; 9 275-281
49 Daldrup-Link H E, Franzius C, Link T M et al.. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol. 2001; 177 229-236
50 Bielack S S, Kempf-Bielack B, Delling G et al.. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20 776-790
51 Abdel-Dayem H M. The role of nuclear medicine in primary bone and soft tissue tumors. Semin Nucl Med. 1997; 27 355-363
52 Jones D N, McCowage G B, Sostman H D et al.. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med. 1996; 37 1438-1444
53 Hawkins D S, Rajendran J G, Conrad III E U, Bruckner J D, Eary J F. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer. 2002; 94 3277-3284
54 Schulte M, Brecht-Krauss D, Werner M et al.. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999; 40 1637-1643
55 Lucas J D, O'Doherty M J, Wong J C et al.. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br. 1998; 80 441-447
56 Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine- 18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998; 25 1244-1247
57 Kato H, Miyazaki T, Nakajima M. 657 Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas. Anticancer Res. 2005; 25 4439-4444
58 Yeh K A, Fortunato L, Ridge J A, Hoffman J P, Eisenberg B L, Sigurdson E R. Routine bone scanning in patients with T1 and T2 breast cancer: a waste of money. Ann Surg Oncol. 1995; 2 319-324
59 Schirrmeister H, Kuhn T, Guhlmann A et al.. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001; 28 351-358
60 Maffioli L, Florimonte L, Pagani L, Butti I, Roca I. Breast cancer: diagnostic and therapeutic options. Eur J Nucl Med Mol Imaging. 2004; 31 S143-S148
61 Smith T J, Davidson N E, Schapira D V et al.. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol. 1999; 17 1080-1082
62 Eubank W B, Mankoff D A. Current and future uses of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2004; 34 224-240
63 Wahl R L. Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol. 2001; 36 250-260
64 Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006; 36 73-92
65 Nakai T, Okuyama C, Kubota T et al.. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005; 32 1253-1258
66 Abe K, Sasaki M, Kuwabara Y et al.. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med. 2005; 19 573-579
67 Lonneux M, Borbath I, Berliere M, Kirkove C, Pauwels S. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging. 2000; 3 45-49
68 Port E R, Yeung H, Gonen M et al.. (18)F-2-fluoro-2-deoxy-d: -glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol. 2006; 13 677-684
69 Lardinois D, Weder W, Hany T F et al.. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003; 348 2500-2507
70 Cheran S K, Herndon J E, Patz E F. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer. 2004; 44 317-325
71 Fricke E, Machtens S, Hofmann M et al.. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med. Mol Imaging. 2003; 30 607-611
72 Schoder H, Larson S M. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004; 34 274-292
73 Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004; 171 2122-2127
74 Shreve P D, Grossman H B, Gross M D, Wahl R L. Metastatic prostate cancer: initial finding of PET 2-deoxyglucose-[F-18]fluoro-D-glucose. Radiology. 1996; 199 751-756
75 Jana S, Blaufox M D. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. 2006; 36 51-72
76 Morris M J, Akhurst T, Osman I et al.. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002; 59 913-918
77 Moog F, Kotzerke J, Reske S N. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med. 1999; 40 1407-1413
78 Schaefer N G, Strobel K, Taverna C, Hany T F. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2007; 34 60-67
79 Guermazi A, Brice P, de Kerviler E E et al.. Extranodal Hodgkin disease: spectrum of disease. Radiographics. 2001; 21 161-179
80 Pakos E E, Fotopoulos A D, Ioannidis J P. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005; 46 958-963
81 Carr R, Barrington S F, Madan B et al.. Detection of lymphoma in bone marrow by whole body positron emission tomography. Blood. 1998; 91 3340-3346
82 Baar J, Burkes R L, Gospodarowicz M. Primary non-Hodgkin's lymphoma of bone. Semin Oncol. 1999; 26 270-275
83 Edeiken-Monroe B, Edeiken J, Kim E E. Radiologic concepts of lymphoma of bone. Radiol Clin North Am. 1990; 28 841-864
84 Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with non-Hodgkin lymphoma and Hodgkin's disease. Radiol Clin North Am. 2007; 45 697-709
85 Durie B G, Waxman A D, D'Agnolo A, Williams C M. Whole-body ¹⁸F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002; 43 1457-1463
86 Schirrmeister H, Bommer M, Buck A K et al.. Initial results in the assessment of multiple myeloma using F-18 FDG PET. Eur J Nucl Med Mol Imaging. 2002; 29 361-366
87 Nanni C, Zamagni E, Farsad M et al.. Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006; 33 525-531
88 Mahfouz T, Miceli M H, Saghafifar F et al.. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005; 23 7857-7863

Einat Even-SapirM.D. Ph.D.

Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center

6 Weizman St., Tel-Aviv, 64239 Israel

eMail: evensap@tasmc.health.gov.il